Rocket Pharmaceuticals (RCKT) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts RCKT Hot Sheet
Join SI Premium – FREE
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q1 EPS of ($0.42), $0.02 worse than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arch Capital (ACGL) PT Raised to $106 at Keefe, Bruyette & Woods
- SK Hynix’s US expansion plans hit snag over China license delays - report
- Jefferies Assumes Huntsman (HUN) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
